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Acute and chronic lung inﬂammation is associated with numerous important disease pathologies including asthma, chronic
obstructivepulmonarydiseaseandsilicosis.Lungﬁbroblastsareanovelandimportanttargetofanti-inﬂammatorytherapy,asthey
orchestrate, respond to, and amplify inﬂammatory cascades and are the key cell in the pathogenesis of lung ﬁbrosis. Peroxisome
proliferator-activated receptor gamma (PPARγ) ligands are small molecules that induce anti-inﬂammatory responses in a variety
oftissues.Here,wereportfortheﬁrsttimethatPPARγ ligandshavepotentanti-inﬂammatoryeﬀectsonhumanlungﬁbroblasts.2-
cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO) and 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) inhibit production of the
inﬂammatory mediators interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), COX-2, and prostaglandin (PG)E2
in primary human lung ﬁbroblasts stimulated with either IL-1β or silica. The anti-inﬂammatory properties of these molecules
are not blocked by the PPARγ antagonist GW9662 and thus are largely PPARγ independent. However, they are dependent on
the presence of an electrophilic carbon. CDDO and 15d-PGJ2, but not rosiglitazone, inhibited NF-κB activity. These results
demonstrate that CDDO and 15d-PGJ2 are potent attenuators of proinﬂammatory responses in lung ﬁbroblasts and suggest that
these molecules should be explored as the basis for novel, targeted anti-inﬂammatory therapies in the lung and other organs.
1.Introduction
Inﬂammation is associated with many diseases of the lung
and can result from immunologic injury, infection, and
inhalation of particulate matter. Diseases strongly associ-
ated with pulmonary inﬂammation include asthma, chronic
obstructive pulmonary disease (COPD), and silicosis. In-
ﬂammation is also associated with an increased susceptibility
to developing lung cancers and other malignancies [1–4].
Aside from glucocorticoids, few eﬀective anti-inﬂammatory
agents exist. In this regard, it is important to investigate new
anti-inﬂammatory targets.
Peroxisome proliferator-activated receptor gamma
(PPARγ) has emerged as an important potential anti-inﬂam-
matory target. PPARγ is a ligand-activated nuclear receptor
that binds a variety of endogenous lipids and lipid-derived
compounds. Upon ligand binding, PPARγ heterodimerizes
with the retinoid X receptor (RXR), translocates to the nu-
cleus, and regulates expression of genes containing PPARγ
response elements (PPREs) [5]. PPARγ ligands regulate key
cellular processes including diﬀerentiation, proliferation,
adipogenesis, and insulin sensitization [6, 7]. PPARγ ligands
have also been shown to attenuate inﬂammation in many
tissues including skin, liver, kidney, and lung [8–11]. Several2 PPAR Research
types of natural PPARγ ligands exist, including prostagl-
andins such as 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2),
and fatty acids such as lysophosphatidic acid and 15S-hy-
droxyeicosatetraenoic acid [12–15]. The thiazolidinedione
(TZD) class of drugs, including rosiglitazone and pio-
glitazone, are synthetic PPARγ agonists that are used as
insulin sensitizers for type II diabetes [16, 17]. 2-cyano-3,
12-dioxoolean-1, 9-dien-28-oic acid (CDDO) is a novel
synthetic triterpenoid PPARγ ligand currently in clinical
trials for treatment of several diﬀerent forms of cancer
[18, 19].
Rosiglitazone, CDDO and 15d-PGJ2 all tightly bind to
PPARγ [12, 20, 21], activate PPARγ-dependent transcription
[22, 23], and regulate adipogenesis via a PPARγ-dependent
mechanism [12, 24, 25]. However, CDDO and 15d-PGJ2
also have eﬀects which can be mediated through PPARγ-
independent pathways [26–28]. 15d-PGJ2 and CDDO con-
tain α/β-unsaturated ketone rings with electrophilic car-
bons susceptible to forming covalent bonds with cellu-
lar proteins through Michaels addition reactions [18, 29,
30]. Rosiglitazone and other synthetic TZDs lack these
electrophilic centers. We have recently demonstrated the
importanceoftheseelectrophiliccarbonsinpreventingTGF-
β-inducedmyoﬁbroblastdiﬀerentiation[26].Understanding
the molecular pathways modulated by PPARγ ligands will
shed light on their potential therapeutic contribution(s) in
the control of pulmonary inﬂammation.
In addition to their structural role, ﬁbroblasts in the
lung act as sentinel cells with signiﬁcant eﬀector roles in
orchestrating and amplifying inﬂammatory cascades. They
become activated when exposed to inﬂammatory stimuli
and produce inﬂammatory mediators such as IL-6, mono-
cyte chemoattractant protein-1 (MCP-1), cyclooxygenase-2
(COX-2), and PGE2 [31–34]. We hypothesized that PPARγ
ligands would exhibit anti-inﬂammatory eﬀects in human
lung ﬁbroblasts, and tested this hypothesis using IL-1β,a
potent proinﬂammatory cytokines, and silica, an inhaled
particulate with strong pro-inﬂammatory eﬀects on lung
ﬁbroblasts [32, 33]. Here, we report for the ﬁrst time that
PPARγ ligands inhibit the inﬂammatory response of human
lung ﬁbroblasts, and do so via a largely PPARγ-independent
pathway dependent on a strong electrophilic center.
2.MaterialandMethods
2.1. Cells and Cell Culture. Primary human lung ﬁbroblasts
were derived from tissue explants obtained from patients
undergoing surgical resection for benign hamartoma. This
is an abnormal but noncancerous growth within the lung, it
is not an inﬂammatory or ﬁbrotic disease. The tissue pieces
used to obtain the ﬁbroblasts were taken from a region of
the resected tissue that was most distal to the hamartoma
that was anatomically and histologically normal [35]. Patient
samples were obtained with approval of the Institutional
Review Board of the University of Rochester. These cells
are morphologically consistent with ﬁbroblasts [36]. They
express collagen and vimentin, and they do not express
CD45, factor VIII, or cytokeratin. Fibroblasts were cultured
in minimum essential media (MEM, Life Technologies,
Gaithersburg, Md, USA) supplemented with 10% fetal bo-
vine serum (FBS, Sigma Aldrich, St. Louis, Mo, USA),
2mML-glutamine, penicillin (100units/mL), streptomycin
(100μg/mL), and amphotericin (0.25μg/mL) (Life Tech-
nologies) at 37◦Ci n7 %C O 2, as previously described [26].
Cells were used at passages 6–12.
2.2. Reagents. PPARγ agonists and related compounds ros-
iglitazone, 9,10-dihydro-15-deoxy-Δ12,14-PGJ2 (CAY10410),
GW9662, and prostaglandin-A1 (PGA1)w e r ef r o mC a y m a n
Chemical (Ann Arbor, MI). 2-cyano-3, 12-dioxoolean-1, 9-
dien-28-oic acid (CDDO) was obtained from the NIH-
RAID Program and Reata Pharmaceuticals (Dallas, Tex,
USA) and 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2)w a s
from Biomol (Plymouth Meeting, PA). These compounds
were prepared as 10mM stocks in DMSO and added to cell
cultures to the ﬁnal concentrations indicated. Control wells
(media only) were supplemented with DMSO to the same
ﬁnal concentration (0.2%) as treated wells. One hour after
pretreatment with PPARγ ligands, inﬂammatory stimulants
interleukin-1β (IL-1β, R&D Systems, Minneapolis, Minn,
USA) and amorphous silica (a generous gift of Dr. David R.
Hemenway, University of Vermont) were added to the cell
cultures at the ﬁnal concentrations indicated for 24 hours.
Amorphous silica was prepared by baking for 2 hours at
180◦C prior to addition to MEM.
2.3. Cytotoxicity Assays. Cell viability was assessed by 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) assay [37]. Fibroblasts were plated in triplicate at a
density of 5,000 cells per well in 96 well plates and treated
with TGF-β and PPARγ agonists for 24h at the indicated
concentrations. MTT was added for the ﬁnal 4 hours. Pro-
d u c t i o no ft h ec o l o r e dr e a c t i o np r o d u c tw a sm e a s u r e da t
560nm, and the results were normalized to the negative con-
trol wells. LDH activity in culture medium was measured by
a commercial assay (Sigma).
2.4. Prostaglandin and Cytokine Assays. Primary human lung
ﬁbroblasts (100,000cells/well) were plated in six-well plates
(Falcon/Becton Dickson, Franklin Lakes, Nj, USA), serum
starved for 48 hours, and treated with IL-1β or silica and/
or PPARγ agonists as described. PGE2 was measured in har-
vested supernatants using a commercially available compet-
itive enzyme immunoassay (EIA) (Cayman Chemical) [38].
IL-6 and CCL2/MCP-1 in harvested supernatants were de-
termined by ELISA according to the manufacturer’s instruc-
tions (R&D Systems, Minneapolis, Minn, USA).
2.5. Western Blots for Cyclooxygenase-2 (COX-2). Total cellu-
lar protein extracts were prepared from lung ﬁbroblast
cultures with 10% Nonidet P-40 (NP-40) lysis buﬀer supple-
mented with a protease inhibitor cocktail (Sigma). Lysates
were clariﬁed by centrifugation and proteins were quan-
titated by the bicinchoninic acid (Pierce, Rockford, IL).
Typically, 5μg of total solubilized cellular protein was sep-
arated by 10% SDS-PAGE under reducing conditionsPPAR Research 3
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Figure 1: PPARγ ligands attenuate IL-6 and MCP-1 production by human lung ﬁbroblasts induced by IL-1β or crystalline silica. Primary
human lung ﬁbroblasts were pretreated with the indicated concentrations of rosiglitazone (Rosi), CDDO or 15d-PGJ2 (PGJ2)f o r1h o u r
and then cotreated with 1ng/mL IL-1β ( a ,b )o r1 0μg/mL crystalline silica (c, d) for 24 hours. Supernatants were harvested and cytokine
concentrationsweredeterminedbyELISA.Resultsaremean ±standarderrorforquadruplicatewellsandarerepresentativeof2independent
experimentsthatyieldedsimilarresults.(e)TheEC50 wasdeterminedfromthegivendataandaveragedforeachcytokine.Datawereanalyzed
by one-way ANOVA. ∗ = P<. 05 compared to stimulus alone (MEM).
and transferred to nitrocellulose membranes. Blots were
probed with a COX-2 speciﬁc monoclonal antibody (Cay-
man Chemical) using GAPDH (Abcam, Cambridge, Mass,
USA) as a loading control. Proteins were visualized with
enhanced chemiluminescence (Western Lightning, Perkin-
Elmer, Wellesley, MA) [38] and densitometry of the resulting
bands was performed using Kodak Molecular Imaging
Software (Rochester, NY) normalized to the loading control.4 PPAR Research
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Figure 2: The PPARγ ligands are not overtly cytotoxic at the doses
used. (a) Primary human lung ﬁbroblasts were treated for 24 hours
with the indicated concentrations of CDDO, or 15d-PGJ2 (PGJ2),
and LDH released into the media was measured by commercial
LDH activity assay. There were no signiﬁcant diﬀerences between
any of the treatment groups compared to MEM control. Results are
mean±standarddeviationfortriplicatewellsandarerepresentative
of 2 independent experiments that yielded similar results. (b)
Primary human lung ﬁbroblasts were plated in a 96-well plate
and treated with the indicated concentrations of CDDO or 15d-
PGJ2 (PGJ2). Cell viability was determined after 24 hours by MTT
assay. The results shown are the mean ± standard deviation of
quadruplicate wells and are normalized to untreated control wells.
2.6. COX-2 Immununﬂuorescence. Fibroblasts were cultured
in eight-well chamber slides (5 × 104 cells/well) in serum-
free MEM for 48 hours before treatment. Some cells were
pretreated with PPARγ agonists for one hour prior to IL-1β
(1ng/mL) treatment for the indicated duration. Cells main-
tained in serum-free MEM were used as negative controls.
Cells were washed in PBS and ﬁxed and permeabilized for
15 minutes at room temperature in BD Cytoﬁx/Cytoperm
solution (BD Biosciences, San Diego, Calif, USA). The
cells were then washed with BD Perm/Wash buﬀer (BD
Biosciences) in this step and all future washes to maintain
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Figure 3: CDDO and 15d-PGJ2 attenuate IL-1β-induced COX-
2 production in human lung ﬁbroblasts. Primary human lung
ﬁbroblasts were pretreated with 20μM rosiglitazone (Rosi), 1μM
CDDO, or 5μM 15d-PGJ2 (PGJ2)f o r1h o u ra n dt h e nc o t r e a t e d
with 1ng/mL of IL-1β for 24 hours. Protein lysates were har-
vested and Western blot analysis was performed by probing for
protein expression of COX-2 and GAPDH (for normalization).
(a) Representative samples are shown. (b) Quadruplicate samples
were analyzed by densitometry and normalized to GAPDH. COX-
2 expression was signiﬁcantly reduced in CDDO and 15d-PGJ2
treated cells compared to IL-1β alone (∗P<. 001). CDDO and 15d-
PGJ2 were signiﬁcantly more potent than rosiglitazone (†P<. 001).
Results are mean ± standard deviation for quadruplicate wells and
arerepresentativeof3independentexperimentsthatyieldedsimilar
results. Data were analyzed by ANOVA.
permeabilization. Nonspeciﬁc sites were blocked with 5%
normal goat serum (Life Technologies) in BD Perm/Wash
buﬀer for 15 minutes at room temperature or 4◦C overnight.
Monoclonalmouseanti-humanCOX-2antibodywasdiluted
in 1% normal goat serum in BD Perm/Wash buﬀer and
incubated with the cells overnight at 4◦C. Cells were washed
and Alexa Fluor 488 (green-) tagged goat anti-mouse IgG
(Invitrogen) diluted in 1% normal goat serum in BD
Perm/Wash buﬀer was added to the cells for one hour at
room temperature. Cells were washed a coverslipped with
ProLong Antifade with DAPI (Invitrogen).
2.7. NF-κB Luciferase Assay. We generated human lung
ﬁbroblast strains that stably expressed a mammalian codon-
optimized ﬁreﬂy luciferase reporter gene under the tran-
scriptional control of NF-κB response elements using NF-κB
Cignal Lenti Reporter lentiviral particles (SABiosciences
Corporation, Frederick, Md, USA) at an MOI = 25. Two days
post-infection, growth medium was removed and replaced
with growth medium containing 1μg/mL puromycin.PPAR Research 5
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Figure 4: Immunoﬂuorescence of human lung ﬁbroblasts demonstrates CDDO and 15d-PGJ2 attenuate IL-1β-induced COX-2 expression.
Fibroblasts were pretreated with PPARγ agonists for 1 hour prior to IL-1β (1ng/mL) treatment for 24 hours. Cells were ﬁxed and
permeabilized and probed for COX-2 protein. COX-2 was visualized with Alexa Fluor 488 (green) and cell nuclei with DAPI (blue). (a)
MEM control; (b) IL-1β;( c )I L - 1 β +2 0μM rosiglitazone; (d) IL-1β +1μMC D DO ;( e )I L - 1 β +5μM 15d-PGJ2,( f)I L - 1 β +5μM CAY10410.
IL-1β-induced COX-2 was inhibited by CDDO (d) and 15d-PGJ2 (e).
Puromycin-resistant clones were identiﬁed and expanded for
propagation. To investigate NF-κB activity, primary human
lung ﬁbroblasts expressing NF-κB-Luc (3,000cells/well)
were plated in 96-well plates, serum starved for 48 hours
and treated with IL-1β and/or PPARγ agonists as described.
C e l l sw e r el y s e di n1 xP a s s i v eL y s i sB u ﬀer and mixed with
LuciferaseAssayReagentIIasinstructedbythemanufacturer
(Promega, Madison, Wis, USA). Equal protein quantities
were used in luciferase assays; results were reported in rel-
ative light units.6 PPAR Research
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Figure 5:PPARγ ligandsattenuateIL-1β-inducedPGE2 production
in human lung ﬁbroblasts. Primary human lung ﬁbroblasts were
pretreated with 20μM rosiglitazone (Rosi), 1μMC D D O ,o r5μM
15d-PGJ2 (PGJ2) and then cotreated with IL-1β for 24 hours as
previously described. Supernatants were harvested, and PGE2 was
determined by EIA. PGE2 production is signiﬁcantly reduced in
PPARγ ligand-treated ﬁbroblasts compared to IL-1β alone (∗P<
.001). CDDO and 15d-PGJ2 were signiﬁcantly more potent than
rosiglitazone (†P<. 05). Results are mean ± standard deviation
for quadruplicate wells and are representative of 3 independent
experiments that yielded similar results. Data were analyzed by
ANOVA.
2.8. Statistics. All data are expressed as mean ± SD. A one-
way analysis of variance (ANOVA) with Tukey post-test
were used to establish statistical signiﬁcance. Results were
considered signiﬁcant if P<. 05.
3. Results
3.1. PPARγ Ligands Inhibit IL-1β-Induced Inﬂammatory
Cytokine Production in Human Lung Fibroblasts. To deter-
mine the eﬃcacy of selected PPARγ ligands in inhibiting
production of inﬂammatory mediators in lung ﬁbroblasts,
primary human lung ﬁbroblasts were pretreated with rosigli-
tazone, CDDO, or 15d-PGJ2 for 1 hour and then co-
treated with a powerful pro-inﬂammatory stimulus, IL-1β
(1ng/mL), for 24 hours. IL-1β strongly induced the pro-
inﬂammatorymediatorsIL-6andMCP-1(Figure 1).Rosigli-
tazone, CDDO, and 15d-PGJ2 all show dose-dependent
inhibition of cytokine production and signiﬁcantly inhibited
the release of these mediators. We also investigated an alter-
native inﬂammatory stimulus, crystalline silica, which we
have previously reported is a potent pro-inﬂammatory
stimulus in human lung ﬁbroblasts [32]. Silica also strongly
induced the production of IL-6 and MCP-1, which was
inhibited by the PPARγ ligands in a dose-dependent man-
ner (Figures 1(c) and 1(d)). Interestingly, all 3 ligands
were 4-5-fold more eﬀective at blocking MCP-1 than IL-6
(Figure 1(e)).
It should be noted that the maximum dose used for each
compound is the highest dose that does not cause overt
cyotoxicity (Figure 2 and data not shown). Rosiglitazone is
at least 10-fold less eﬀective than CDDO or 15d-PGJ2 and is
a very poor inhibitor of IL-6 release even at the maximum
tolerable dose of 20μM.
3.2. PPARγ Ligands Inhibit IL-1β-Induced Upregulation of
COX-2 and PGE2. To further evaluate the potential antiin-
ﬂammatory actions of PPARγ ligands, lung ﬁbroblasts were
treated with IL-1β and PPARγ ligands, and expression of
COX-2 was determined by Western blot. As expected, IL-
1β strongly induces COX-2 (Figure 3). CDDO and 15d-PGJ2
signiﬁcantly inhibited IL-1β-induced COX-2 production.
However, rosiglitazone failed to suppress COX-2 induction
in human lung ﬁbroblasts.
We also performed immunoﬂuorescence to conﬁrm the
induction of COX-2 protein and to localize the expres-
sion of COX-2 in IL-1β-treated lung ﬁbroblasts. COX-2-
speciﬁc staining demonstrated that untreated ﬁbroblasts
expressed minimal COX-2 at baseline (Figure 4(a)). Upon
treatment with IL-1β, cytoplasmic COX-2 production was
markedly upregulated (Figure 4(b)). Rosiglitazone failed to
suppress IL-1β-induced COX-2 upregulation (Figure 4(c)).
In contrast, however, both CDDO and 15d-PGJ2 suppressed
cytoplasmicexpressionofCOX-2inIL-1β-treatedﬁbroblasts
(Figures 4(d) and 4(e)). CAY10410, a structural analogue of
15d-PGJ2, did not suppress IL-1β-induced COX-2 upregula-
tion (Figure 4(f)), suggesting structural diﬀerences between
the ligands account for their anti-inﬂammatory actions.
COX-2 mediates the ﬁrst step in the conversion of ar-
achidonic acid to prostaglandins. The immunomodulato-
ry prostaglandin PGE2, a product of this reaction, was
measured in lung ﬁbroblast culture supernatants following
treatment with PPARγ ligands and IL-1β. Consistent with
the COX-2 results, CDDO and 15d-PGJ2 inhibited IL-1β-
induced production of PGE2 by greater than 90% compared
to controls treated with IL-1β alone (Figure 5). Rosiglitazone
also inhibited IL-1β-induced production of PGE2,b u tw a s
less eﬀective than CDDO and 15d-PGJ2.
3.3. Suppression of Inﬂammatory Mediators by PPARγ Ligands
in Human Lung Fibroblasts Occurs via a PPARγ-Independent
Mechanism. We used a pharmacological approach to deter-
mine whether the anti-inﬂammatory actions of PPARγ
ligandsaredependentonorindependentofPPARγ.GW9662
is an irreversible PPARγ antagonist that covalently binds to
a cysteine residue in the ligand binding site of PPARγ [39].
GW9662 inhibits PPARγ agonist-driven adipogenesis, which
is a completely PPARγ-dependent process [24]. Primary
human lung ﬁbroblasts were pretreated for 4 hours with
GW9662andonehourwithCDDOor15d-PGJ2,followedby
IL-1β.I L - 1 β strongly induced IL-6, MCP-1 and PGE2 com-
pared to MEM control (Figures 6(a)–6(c)). As previously
shown, CDDO and 15d-PGJ2 signiﬁcantly inhibited the IL-
1β-induced production of these inﬂammatory mediators.
GW9662didnotreversethesuppressiveeﬀectsofCDDOand
15d-PGJ2 ligands on cytokine and PGE2 production (Figures
6(a)–6(c)). This indicates that PPARγ is not essential for the
anti-inﬂammatory eﬀects of these ligands, and that PPARγ
independent pathways are therefore likely important.PPAR Research 7
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Figure 6: The PPARγ antagonist GW9662 does not inhibit the anti-inﬂammatory eﬀects of CDDO and 15d-PGJ2. Primary human lung
ﬁbroblasts were pretreated with 1μM GW9662 for 3 hours, then PPARγ ligands were added for 1 hour, then 1ng/mL IL-1β was added for
24 hours. Supernatants were harvested and proinﬂammatory mediators were measured by ELISA or EIA. (a) IL-6, (b) MCP-1, (c) PGE2.
Pretreatment with GW9662 did not signiﬁcantly alter the attenuation of pro-inﬂammatory mediator production by CDDO or 15d-PGJ2
alone. Results are mean ± standard deviation for quadruplicate wells and are representative of 2 independent experiments that yielded
similar results.
3.4. A Strong Electrophilic Center Is Important for PPARγ Li-
gand-Mediated Suppression of Inﬂammation in Human Lung
Fibroblasts. CDDO and 15d-PGJ2 contain α/β-unsaturated
ketone rings with electrophilic carbons that can form
covalent bonds with free sulfhydryls in cellular proteins
[40, 41]. CAY10410 (9,10-dihydro-15-deoxy-Δ12,14-PGJ2)i s
a structural analog of 15d-PGJ2 that lacks the unsaturated
ketone containing the electrophilic carbon. To investigate
the importance of the electrophilic center in suppressing
inﬂammatory endpoints, we compared the ability of 15d-
PGJ2 and CAY10410 to inhibit the pro-inﬂammatory eﬀects
of IL-1β on human lung ﬁbroblasts. CAY10410 treatment
resulted in a small reduction in IL-1β-induced IL-6 produc-
tionthatwasnotstatisticallysigniﬁcant,anda60%reduction
in MCP-1 production compared to 98% inhibition by 15d-
PGJ2 (Figure 7).
To further investigate the importance of the electrophilic
center, we tested another prostaglandin that is also a potent
electrophile, PGA1.P G A 1 was partially eﬀective at inhibiting
IL-1β-inducedproductionofIL-6andcompletelyeﬀectivein
blocking MCP-1 production (Figure 7).
3.5. A Strong Electrophilic Center Is Important for PPARγ
Ligand-Mediated Suppression of NF-κBi nH u m a nL u n g
Fibroblasts. To better understand the mechanism involved
in PPARγ ligand-mediated immune suppression, we inves-
tigated the eﬀect of PPARγ ligands on the activation of
NF-κB, a transcription factor that regulates the expression
of numerous pro-inﬂammatory mediators. Primary human
lung ﬁbroblasts were transfected with an NF-κBl u c i f e r a s e
reporter construct, and treated with PPARγ ligands and IL-
1β. CDDO, 15d-PGJ2,a n dP G A 1, but not CAY10410 or
rosiglitazone, signiﬁcantly decreased IL-1β-induced NF-κB
luciferase activity (Figure 8).
4. Discussion
Inﬂammation is associated with many diseases of the lung
including asthma, chronic obstructive pulmonary disease
(COPD), silicosis, and lung cancer [1–4]. Aside from
glucocorticoids, there are few eﬀective anti-inﬂammatory
therapies; therefore, the development of novel therapies that8 PPAR Research
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Figure 7: A strong electrophilic carbon is necessary for PPARγ
ligand-mediated attenuation of inﬂammation in IL-1β-treated
human lung ﬁbroblasts. Primary human lung ﬁbroblasts were pre-
treated with 1μMC D D O ,5μM 15d-PGJ2 (PGJ2), 5μM CAY10410,
(CAY) or 15μMP G A 1 for 1 hour and then co-treated with 1ng/mL
of IL-1β for 24 hours. Supernatants were harvested, and cytokine
concentrations were measured by ELISA. (a) CDDO, 15d-PGJ2,
and PGA1, but not CAY10410, signiﬁcantly inhibited production
of IL-6 (∗P<. 01). (b) CDDO, 15d-PGJ2,P G A 1, and CAY10410
all signiﬁcantly reduced MCP-1 production (∗P<. 01). CDDO,
15d-PGJ2,andPGA1 weresigniﬁcantlymorepotentthanCAY10410
(†P<. 01).Resultsaremean ±standarddeviationforquadruplicate
wells and are representative of 3 independent experiments.
have the potential to alleviate pulmonary diseases associated
with inﬂammatory etiologies is a priority.
PPARγ ligands are receiving increasing attention as po-
tential anti-inﬂammatory therapeutics because of their anti-
inﬂammatory properties in a variety of tissues in vivo and
cells in vitro [42]. The anti-inﬂammatory eﬀects of PPARγ
ligands have not previously been reported in human lung
ﬁbroblasts, a sentinel cell of inﬂammatory cascades in the
lung[31,34,43,44].Here,wereportthatPPARγ ligandshave
potent anti-inﬂammatory eﬀects in human lung ﬁbroblasts
exposed to divergent inﬂammatory stimuli, and that the
mechanism is largely PPARγ-independent.
To induce a pro-inﬂammatory response in human lung
ﬁbroblasts, we used two diﬀerent inﬂammatory stimuli. IL-
1β is an acute phase inﬂammatory cytokine, while silica
is a particulate that has potent proinﬂammatory eﬀects
when inhaled and is capable of causing both acute and
chronic inﬂammatory lung disease [32, 33]. Both IL-1β and
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Figure 8: CDDO and PGA1 inhibit IL-1β-induced NF-κBt r a n -
scriptional activity in human lung ﬁbroblasts. Primary human
lung ﬁbroblasts were transfected with a luciferase reporter, then
pretreated with 20μM rosiglitazone (Rosi), 1μMC D D O ,5 μM
15d-PGJ2 (PGJ2), 5μM CAY10410 (CAY), or 15μMP G A 1 and
cotreatedwithofIL-1βfor24hoursasdescribed.NF-κB-dependent
luciferase activity was measured in lysates as described, normalized
to protein concentration, and expressed as relative light units
(RLU). NF-κB activation is signiﬁcantly reduced in PPARγ ligand-
treated ﬁbroblasts compared to IL-1β alone (∗P<. 01). Results
are mean ± standard deviation for quadruplicate wells and are
representative of 2 independent experiments that yielded similar
results.
silica induced the inﬂammatory mediators IL-6 and MCP-
1, which were inhibited by CDDO, rosiglitazone, and 15d-
PGJ2 (Figure 1). Interestingly, rosiglitazone was much less
eﬀective at inhibiting IL-6 and MCP-1, with an EC50 5–
10-fold higher than 15d-PGJ2 and at least 30-fold higher
than CDDO. CDDO and 15d-PGJ2, but not rosiglitazone,
also blocked upregulation of COX-2 and PGE2 (Figures 3
and 4). This is in agreement with our previous ﬁnding that
r o s i g l i t a z o n ei sl e s se ﬀective than CDDO or 15d-PGJ2 at
inhibitingthepro-ﬁbroticeﬀectsofTGF-βinlungﬁbroblasts
[26], and suggests that there are signiﬁcant diﬀerences in the
mechanism of action between rosiglitazone and CDDO and
15d-PGJ2.
Rosiglitazone, CDDO and 15d-PGJ2 all tightly bind the
PPARγ receptor [12, 20, 21], activate PPARγ-dependent
transcription [22, 23], and promote adipogenesis via a
solely PPARγ-dependent mechanism [12, 25]. However, in
addition to stimulating PPARγ-dependent transcriptional
changes, CDDO and 15d-PGJ2 a r er e p o r t e dt oh a v ee ﬀects
that are mediated through PPARγ-independent pathways
[26, 28, 45]. To determine whether CDDO, and 15d-PGJ2
might be acting via a PPARγ-independent mechanism, we
used a pharmacological approach to block PPARγ. GW9662
is an irreversible competitive PPARγ antagonist that cova-
lently binds to a cysteine residue in the ligand bindingPPAR Research 9
domain of PPARγ [46]. GW9662 is a highly eﬀective inhib-
itor of PPARγ-dependent processes including diﬀerentiation
of osteoclasts and activation of hepatic stellate cells [47,
48]. We have previously reported that rosiglitazone, CDDO
and 15d-PGJ2 drive the diﬀerentiation of ﬁbroblasts to
adipocytes. GW9662 at 1μM completely inhibits this eﬀect,
demonstrating that this compound is eﬀective at blocking
the PPARγ-dependent actions of these PPARγ ligands [24].
Here, GW9662 did not reverse the anti-inﬂammatory eﬀects
of CDDO and 15d-PGJ2 (Figure 6), indicating that the anti-
inﬂammatory eﬀects of CDDO and 15d-PGJ2 on human
lung ﬁbroblasts are largely independent of the PPARγ-de-
pendent transcriptional pathway. Rosiglitazone was such a
poor inhibitor of the inﬂammatory eﬀects of IL-1β that it
was not possible to show a reversal of inhibition by GW9662,
which would be expected if rosiglitazone acted by a purely
PPARγ-dependent mechanism.
Comparing the chemical structures of rosiglitazone,
CDDO, and 15d-PGJ2, it is notable that CDDO and 15d-
PGJ2 havestrongelectrophiliccarbons,whereasrosiglitazone
does not. 15d-PGJ2 has one α/β-unsaturated ketone ring
with an electrophilic carbon capable of forming covalent
bonds through Michael addition reactions [49], whereas
CDDO has two [18, 30]. We have recently demonstrated the
importanceoftheseelectrophiliccarbonsinpreventingTGF-
β-inducedmyoﬁbroblast diﬀerentiation [26, 50]. We hy-
pothesize that the electrophilic carbons of CDDO and 15d-
PGJ2 are also important for their anti-inﬂammatory eﬀects.
To test this hypothesis, we used CAY10410, a structural an-
alog of 15d-PGJ2 that lacks the α/β-unsaturated ketone, and
PGA1, another electrophilic prostaglandin. In lung ﬁbro-
blastsstimulatedwithIL-1β,CAY10410didnotinhibitCOX-
2u p r e g u l a t i o no rI L - 6p r o d u c t i o na n dw a sh a l fa se ﬀective
as 15d-PGJ2 at blocking MCP-1 production (Figures 4 and
7). On the other hand, PGA1 signiﬁcantly attenuated IL-
6 and completely blocked production of MCP-1 (Figure 7).
Because CAY10410 has an identical structure to 15d-PGJ2
except for the electrophilic carbon, the fact that CAY10410
lacks the eﬀects of 15d-PGJ2 strongly suggests that the elec-
trophilic centers present in CDDO and 15d-PGJ2 are critical
for mediating their maximal anti-inﬂammatory therapeu-
tic potential. CDDO and 15d-PGJ2, but not rosiglitazone
or CAY10410, signiﬁcantly inhibited IL-1β-induced NF-κB
activity (Figure 8).
ThemoleculartargetsofCDDOand15d-PGJ2 ininﬂam-
mation are not completely known. 15d-PGJ2 can bind to the
NF-κB components IκB and p65 [50]. Another candidate is
the transcription factor Nrf2, which regulates anti-oxidant
and anti-inﬂammatory pathways. CDDO and 15d-PGJ2
activate Nrf2 in mouse cells and human cancer cells [51, 52].
However, these compounds do not activate Nrf2 in human
lung ﬁbroblasts [27, 53]. We have previously reported that
CDDO activates AP-1 transcriptional activity in human lung
ﬁbroblasts [27]. However, AP-1 is a promoter, rather than
an inhibitor of inﬂammation, and AP-1 activation leads
to upregulation of IL-6 via NF-κB[ 54]. We hypothesize
that these electrophilic compounds suppress inﬂammation
and activate AP-1 via diﬀerent pathways, and that the anti-
inﬂammatory eﬀects are stronger and override the poten-
tially proinﬂammatory eﬀects of AP-1 activation.
In addition to PPARγ-independent eﬀects, PPARγ lig-
ands have anti-inﬂammatory eﬀects that are moderated
viaaPPARγ-dependent mechanism. This PPARγ-dependent
mechanism can be accessed by TZDs such as rosiglitazone
and pioglitazone [9, 55–57], and indeed, rosiglitazone has
limited anti-inﬂammatory properties in this report. How-
ever,whileTZDsarecurrentlyusedclinicallyasinsulinsensi-
tizersintype2diabetes,theyhaveacomplexsideeﬀectproﬁle
including edema, weight gain, bone weakness, and poten-
tially an increased risk of cardiovascular disease [58–60],
that may limit their widespread use as anti-inﬂammatory
therapies. Although TZDs have high binding aﬃnity for
PPARγ they lack electrophilic centers and are thus unable
to access PPARγ-independent anti-inﬂammatory pathways
that use this mechanism [27, 49, 61, 62]. We suggest
that additional research on the PPARγ-independent anti-
inﬂammatory activities of CDDO and 15d-PGJ2, including
identiﬁcation of additional targets beyond NF-κB, should
lead to development of novel compounds with greater speci-
ﬁcity for the anti-inﬂammatory targets of PPARγ ligands but
decreased binding of PPARγ itself, with fewer resulting side-
eﬀects. As CDDO is orally active, has a long half-life, and is
currentlyinclinicaltrialsasananticancertherapy,itmaybea
useful platform for derivatization and further study. Further
development of small compounds with strong electrophilic
centers is warranted as these drugs may be eﬀective anti-
inﬂammatory treatments for human lung diseases.
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